Healthcare Industry News: radiopharmaceuticals
News Release - June 13, 2008
Positron Corporation Announces Sales & Marketing Agreement with NuView RadiopharmaceuticalsHOUSTON--(HSMN NewsFeed)--Positron Corporation (OTC: POSC ) (the “Company”) announced today that it has entered into an exclusive sales and marketing agent agreement with NuView radiopharmaceuticals.
NuView radiopharmaceuticals will act as exclusive agent for Positron’s brand of PET, SPECT and automated dose dispensing systems. NuView has an established network of 35 experienced salespeople strategically located across the country.
NuView will be displaying Positron’s molecular imaging products, and debuting their next generation cost effective PET scanner, at the annual meeting of the Society of Nuclear Medicine in New Orleans beginning June 14, 2008.
“We're very pleased to have been selected by Positron to represent their automated dose drawing, SPECT and PET diagnostic imaging technologies in the US,” said Paul Crowe, CEO of NuView. Crowe also stated, “Positron is introducing the first dedicated cardiac PET unit for the private practice physician. The clinical imaging benefits of PET over other imaging modalities are well established. The low price point of this new PET System, allows for economically bundling the radiopharmaceuticals utilized with the procedure not available before. The PET devices small footprint makes it the ideal system for private offices or clinic settings. For existing mobile or fixed site service providers, the Positron PET System opens up a brand new opportunity to expand current utilization.”
"We are looking forward to NuView rapidly expanding the recognition of our brand. Our SPECT system combined with the newly acquired Pharm-AssistTM from Dose Shield is a perfect combination to introduce a total solution to Nuclear Cardiologists,” stated Joe Oliverio, President of Positron. Oliverio also stated, “There is also a significant amount of attention on cardiac PET at this time. Our introduction of a cost effective, dedicated cardiac PET unit, alternative into this market will offer cardiologists the opportunity to provide patients with a more accurate diagnosis, an opportunity to increase their revenues, save healthcare dollars and at the same time improve patient outcomes."
About NuView radiopharmaceuticals
NuView radiopharmaceuticals, Inc. is a privately held, emerging Life Sciences Company based in Park City, Utah. NuView radiopharmaceuticals, Inc.'s core business is identifying and developing new, novel radiopharmaceuticals for the molecular imaging sector. NuView pursues opportunities to represent and distribute complimentary product lines from other companies in nuclear medicine. Some of the technologies NuView represents include a compound pharmacy line of generic radiopharmaceuticals, new on-site dose dispensing technologies for safety and operating efficiencies, and selected SPECT and PET imaging technologies which together provide a turn-key source for the delivery of high quality Nuclear Medicine and Nuclear Cardiology services.
Additional information may be found at www.nuviewinfo.com.
About Positron Corporation
Positron Corporation is a growing healthcare company offering cardiac molecular imaging solutions that will transform the delivery of healthcare through radiopharmaceutical development, advancing imaging technology and by introducing unique disease management applications into the market. Positron Corporation designs, manufactures and sells SPECT, PET and automated dose delivery devices in to the Nuclear Medicine market. Additional information may be found at www.positron.com.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by Positron Corporation are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing and other uncertainties described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.
For any additional information contact Positron’s President, Joe Oliverio at (281) 492-7100.
Source: Positron Corporation
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.